Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Kenvue Inc. Common Stock (KVUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Kenvue Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B). The key difference: Kenvue Inc. Common Stock is far larger — about 2.7× Halozyme Therapeutics Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HALO | KVUE | |
|---|---|---|
Market Cap | $12.58B | $34.06B |
Volume | 2,179,278 | 23,267,228 |
Sector | Health | Consumer Staples |
52-Week High | $115.22 | $19.83 |
52-Week Low | $61.63 | $14.11 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $14.49B | $41.56B |
Dividend Yield | — | 4.74% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →
